Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

A single domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor.

Ferrière S, Kawecki C, Ottavi JF, Denis CV, Kauskot A, Christophe OD, Lenting PJ.

J Thromb Haemost. 2019 Aug 18. doi: 10.1111/jth.14615. [Epub ahead of print]

PMID:
31423724
2.

Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.

Aymonnier K, Kawecki C, Venisse L, Boulaftali Y, Christophe OD, Lenting PJ, Arocas V, de Raucourt E, Denis CV, Bouton MC.

Blood. 2019 Aug 5. pii: blood.2019000281. doi: 10.1182/blood.2019000281. [Epub ahead of print]

PMID:
31383642
3.

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]

4.

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.

Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, Vignaud A, van Wittenberghe L, Manni G, Christophe O, Fallarino F, Roy C, Michaud A, Ilyinskii P, Kishimoto TK, Mingozzi F.

Nat Commun. 2018 Oct 5;9(1):4098. doi: 10.1038/s41467-018-06621-3.

5.

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

Muczynski V, Casari C, Moreau F, Aymé G, Kawecki C, Legendre P, Proulle V, Christophe OD, Denis CV, Lenting PJ.

Blood. 2018 Sep 13;132(11):1193-1197. doi: 10.1182/blood-2018-01-829523. Epub 2018 Jul 31.

PMID:
30064978
6.

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Casari C, Paul DS, Susen S, Lavenu-Bombled C, Harroche A, Piatt R, Poe KO, Lee RH, Bryckaert M, Christophe OD, Lenting PJ, Denis CV, Bergmeier W.

Blood Adv. 2018 Jun 26;2(12):1417-1428. doi: 10.1182/bloodadvances.2017014290.

7.

Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability.

Adam F, Kauskot A, Kurowska M, Goudin N, Munoz I, Bordet JC, Huang JD, Bryckaert M, Fischer A, Borgel D, de Saint Basile G, Christophe OD, Ménasché G.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1037-1051. doi: 10.1161/ATVBAHA.117.310373. Epub 2018 Mar 8.

PMID:
29519941
8.

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

Wohner N, Muczynski V, Mohamadi A, Legendre P, Proulle V, Aymé G, Christophe OD, Lenting PJ, Denis CV, Casari C.

Haematologica. 2018 Apr;103(4):728-737. doi: 10.3324/haematol.2017.175216. Epub 2018 Jan 11.

9.

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.

Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F, Simon Sola M, Charles S, Ronzitti G, Vignaud A, van Wittenberghe L, Marolleau B, Jouen F, Tan S, Boyer O, Christophe O, Brisson AR, Maguire CA, Mingozzi F.

Blood Adv. 2017 Oct 16;1(23):2019-2031. doi: 10.1182/bloodadvances.2017010181. eCollection 2017 Oct 24.

10.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Dec 7;130(23):2463-2468. doi: 10.1182/blood-2017-08-801662. Epub 2017 Oct 17. Review.

11.

Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

Muczynski V, Christophe OD, Denis CV, Lenting PJ.

Semin Thromb Hemost. 2017 Sep;43(6):581-590. doi: 10.1055/s-0037-1604053. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750425
12.

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, Christophe OD, Lenting PJ.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1736-1740. doi: 10.1161/ATVBAHA.117.309319. Epub 2017 Jun 22.

PMID:
28642239
13.

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

Muczynski V, Aymé G, Regnault V, Vasse M, Borgel D, Legendre P, Bazaa A, Harel A, Loubière C, Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Apr 27;129(17):2443-2454. doi: 10.1182/blood-2016-06-724351. Epub 2017 Feb 17.

14.

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.

Pepin M, Mezouar S, Pegon J, Muczynski V, Adam F, Bianchini EP, Bazaa A, Proulle V, Rupin A, Paysant J, Panicot-Dubois L, Christophe OD, Dubois C, Lenting PJ, Denis CV.

Sci Rep. 2016 Nov 28;6:37953. doi: 10.1038/srep37953.

15.

Network-based analysis of omics data: the LEAN method.

Gwinner F, Boulday G, Vandiedonck C, Arnould M, Cardoso C, Nikolayeva I, Guitart-Pla O, Denis CV, Christophe OD, Beghain J, Tournier-Lasserve E, Schwikowski B.

Bioinformatics. 2017 Mar 1;33(5):701-709. doi: 10.1093/bioinformatics/btw676.

16.

LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex.

Fazavana JG, Muczynski V, Proulle V, Wohner N, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2016 Dec;14(12):2458-2470. doi: 10.1111/jth.13502. Epub 2016 Oct 25.

17.

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Aymé G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa JP, Lenting PJ, Bryckaert M, Denis CV, Baruch D.

JCI Insight. 2016 Oct 6;1(16):e88643. doi: 10.1172/jci.insight.88643.

18.

A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Adam F, Casari C, Prévost N, Kauskot A, Loubière C, Legendre P, Repérant C, Baruch D, Rosa JP, Bryckaert M, de Groot PG, Christophe OD, Lenting PJ, Denis CV.

Sci Rep. 2016 May 23;6:26306. doi: 10.1038/srep26306.

19.

Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis.

Khatib AM, Lahlil R, Hagedorn M, Delomenie C, Christophe O, Denis C, Siegfried G.

Oncotarget. 2016 Mar 15;7(11):12102-20. doi: 10.18632/oncotarget.7728.

20.

Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.

Berrou E, Kauskot A, Adam F, Harel A, Legendre P, Lavenu Bombled C, Rothschild C, Prevost N, Christophe OD, Lenting PJ, Denis CV, Rosa JP, Bryckaert M.

PLoS One. 2015 Dec 8;10(12):e0143896. doi: 10.1371/journal.pone.0143896. eCollection 2015.

21.

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X.

Muczynski V, Bazaa A, Loubière C, Harel A, Cherel G, Denis CV, Lenting PJ, Christophe OD.

Blood. 2016 Feb 11;127(6):778-86. doi: 10.1182/blood-2015-05-647032. Epub 2015 Nov 25.

22.

Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.

Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2015 May;13(5):815-20. doi: 10.1111/jth.12885. Epub 2015 Mar 31.

23.

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.

Lenting PJ, Christophe OD, Denis CV.

Blood. 2015 Mar 26;125(13):2019-28. doi: 10.1182/blood-2014-06-528406. Epub 2015 Feb 23. Review.

24.

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.

Thromb Haemost. 2014 Nov;112(5):1014-23. doi: 10.1160/TH14-02-0148. Epub 2014 Jul 17.

PMID:
25030452
25.

Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates.

Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, Nair N, Willems J, Evens H, Rincon MY, Matrai J, Di Matteo M, Samara-Kuko E, Yan B, Acosta-Sanchez A, Meliani A, Cherel G, Blouin V, Christophe O, Moullier P, Mingozzi F, VandenDriessche T.

Mol Ther. 2014 Sep;22(9):1605-13. doi: 10.1038/mt.2014.114. Epub 2014 Jun 23.

26.

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

Morioka Y, Casari C, Wohner N, Cho S, Kurata S, Kitano A, Christophe OD, Lenting PJ, Li R, Denis CV, Prévost N.

Blood. 2014 May 22;123(21):3344-53. doi: 10.1182/blood-2013-10-531392. Epub 2014 Apr 8.

27.

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

Casari C, Berrou E, Lebret M, Adam F, Kauskot A, Bobe R, Desconclois C, Fressinaud E, Christophe OD, Lenting PJ, Rosa JP, Denis CV, Bryckaert M.

J Clin Invest. 2013 Dec;123(12):5071-81. doi: 10.1172/JCI69458. Epub 2013 Nov 25.

28.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.

Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S.

Blood. 2014 Jan 2;123(1):121-5. doi: 10.1182/blood-2013-04-495853. Epub 2013 Sep 6.

29.

Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.

Casari C, Du V, Wu YP, Kauskot A, de Groot PG, Christophe OD, Denis CV, de Laat B, Lenting PJ.

Blood. 2013 Oct 17;122(16):2893-902. doi: 10.1182/blood-2013-03-493312. Epub 2013 Aug 14.

30.

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.

Casari C, Lenting PJ, Christophe OD, Denis CV.

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013047. doi: 10.4084/MJHID.2013.047. Print 2013.

31.

On the versatility of von Willebrand factor.

Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ.

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013046. doi: 10.4084/MJHID.2013.046. Print 2013.

32.

Clearance of von Willebrand factor.

Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV.

J Thromb Haemost. 2013 Jun;11 Suppl 1:202-11. doi: 10.1111/jth.12226. Review.

33.

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, Morton CL, Davidoff AM, Nathwani AC.

Blood. 2013 Apr 25;121(17):3335-44. doi: 10.1182/blood-2012-10-462200. Epub 2013 Feb 20.

34.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Legendre P, Navarrete AM, Rayes J, Casari C, Boisseau P, Ternisien C, Caron C, Fressinaud E, Goudemand J, Veyradier A, Denis CV, Lenting PJ, Christophe OD.

Blood. 2013 Mar 14;121(11):2135-43. doi: 10.1182/blood-2012-09-456038. Epub 2013 Jan 18.

35.

Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance.

Kurdi M, Cherel G, Lenting PJ, Denis CV, Christophe OD.

PLoS One. 2012;7(9):e45111. doi: 10.1371/journal.pone.0045111. Epub 2012 Sep 25.

36.

von Willebrand factor: the old, the new and the unknown.

Lenting PJ, Casari C, Christophe OD, Denis CV.

J Thromb Haemost. 2012 Dec;10(12):2428-37. doi: 10.1111/jth.12008. Review.

37.

A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor.

Navarrete AM, Casari C, Legendre P, Marx I, Hu JR, Lenting PJ, Christophe OD, Denis CV.

Blood. 2012 Sep 27;120(13):2723-32. Epub 2012 Aug 20.

38.

Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Pegon JN, Kurdi M, Casari C, Odouard S, Denis CV, Christophe OD, Lenting PJ.

Haematologica. 2012 Dec;97(12):1855-63. doi: 10.3324/haematol.2012.063297. Epub 2012 Jun 24.

39.

In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Badirou I, Kurdi M, Legendre P, Rayes J, Bryckaert M, Casari C, Lenting PJ, Christophe OD, Denis CV.

PLoS One. 2012;7(5):e37508. doi: 10.1371/journal.pone.0037508. Epub 2012 May 17.

40.

Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.

Dimitrov JD, Christophe OD, Kang J, Repessé Y, Delignat S, Kaveri SV, Lacroix-Desmazes S.

Biochemistry. 2012 May 22;51(20):4108-16. doi: 10.1021/bi300232d. Epub 2012 May 14.

PMID:
22559004
41.

Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor.

Saint-Lu N, Oortwijn BD, Pegon JN, Odouard S, Christophe OD, de Groot PG, Denis CV, Lenting PJ.

Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):894-901. doi: 10.1161/ATVBAHA.111.240309. Epub 2012 Jan 19.

PMID:
22267483
42.

Macrophage LRP1 contributes to the clearance of von Willebrand factor.

Rastegarlari G, Pegon JN, Casari C, Odouard S, Navarrete AM, Saint-Lu N, van Vlijmen BJ, Legendre P, Christophe OD, Denis CV, Lenting PJ.

Blood. 2012 Mar 1;119(9):2126-34. doi: 10.1182/blood-2011-08-373605. Epub 2012 Jan 10.

43.

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2012 Mar;18(2):248-54. doi: 10.1111/j.1365-2516.2011.02679.x. Epub 2011 Nov 2.

PMID:
22044692
44.

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S.

Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3.

45.

von Willebrand factor clearance does not involve proteolysis by ADAMTS-13.

Badirou I, Kurdi M, Rayes J, Legendre P, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2010 Oct;8(10):2338-40. doi: 10.1111/j.1538-7836.2010.04012.x. No abstract available.

46.

Factor VIII and von Willebrand factor--too sweet for their own good.

Lenting PJ, Pegon JN, Christophe OD, Denis CV.

Haemophilia. 2010 Jul;16 Suppl 5:194-9. doi: 10.1111/j.1365-2516.2010.02320.x. Review.

PMID:
20590881
47.

Two residues in the activation peptide domain contribute to the half-life of factor X in vivo.

Guéguen P, Cherel G, Badirou I, Denis CV, Christophe OD.

J Thromb Haemost. 2010 Jul;8(7):1651-3. doi: 10.1111/j.1538-7836.2010.03905.x. Epub 2010 May 4. No abstract available.

48.

Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.

Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, Christophe OD, Lenting PJ, Denis CV.

Blood. 2010 Jun 10;115(23):4870-7. doi: 10.1182/blood-2009-11-254193. Epub 2010 Mar 3.

49.

Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.

Navarrete A, Dasgupta S, Delignat S, Caligiuri G, Christophe OD, Bayry J, Nicoletti A, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2009 Nov;7(11):1816-23. doi: 10.1111/j.1538-7836.2009.03571.x. Epub 2009 Aug 11.

50.

Mouse models of von Willebrand disease.

Pendu R, Christophe OD, Denis CV.

J Thromb Haemost. 2009 Jul;7 Suppl 1:61-4. doi: 10.1111/j.1538-7836.2009.03411.x. Review.

Supplemental Content

Loading ...
Support Center